112 related articles for article (PubMed ID: 9850068)
1. Protection of metabolic and exercise capacity in unselected weight-losing cancer patients following treatment with recombinant erythropoietin: a randomized prospective study.
Daneryd P; Svanberg E; Körner U; Lindholm E; Sandström R; Brevinge H; Pettersson C; Bosaeus I; Lundholm K
Cancer Res; 1998 Dec; 58(23):5374-9. PubMed ID: 9850068
[TBL] [Abstract][Full Text] [Related]
2. Palliative nutritional intervention in addition to cyclooxygenase and erythropoietin treatment for patients with malignant disease: Effects on survival, metabolism, and function.
Lundholm K; Daneryd P; Bosaeus I; Körner U; Lindholm E
Cancer; 2004 May; 100(9):1967-77. PubMed ID: 15112279
[TBL] [Abstract][Full Text] [Related]
3. Insulin treatment in cancer cachexia: effects on survival, metabolism, and physical functioning.
Lundholm K; Körner U; Gunnebo L; Sixt-Ammilon P; Fouladiun M; Daneryd P; Bosaeus I
Clin Cancer Res; 2007 May; 13(9):2699-706. PubMed ID: 17473202
[TBL] [Abstract][Full Text] [Related]
4. Evidence that long-term COX-treatment improves energy homeostasis and body composition in cancer patients with progressive cachexia.
Lundholm K; Daneryd P; Körner U; Hyltander A; Bosaeus I
Int J Oncol; 2004 Mar; 24(3):505-12. PubMed ID: 14767534
[TBL] [Abstract][Full Text] [Related]
5. Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care--correlations with food intake, metabolism, exercise capacity, and hormones.
Fouladiun M; Körner U; Bosaeus I; Daneryd P; Hyltander A; Lundholm KG
Cancer; 2005 May; 103(10):2189-98. PubMed ID: 15822132
[TBL] [Abstract][Full Text] [Related]
6. Effects of recombinant erythropoietin in palliative treatment of unselected cancer patients.
Lindholm E; Daneryd P; Körner U; Hyltander A; Fouladiun M; Lundholm K
Clin Cancer Res; 2004 Oct; 10(20):6855-64. PubMed ID: 15501962
[TBL] [Abstract][Full Text] [Related]
7. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
[TBL] [Abstract][Full Text] [Related]
8. Epoetin alfa for protection of metabolic and exercise capacity in cancer patients.
Daneryd P
Semin Oncol; 2002 Jun; 29(3 Suppl 8):69-74. PubMed ID: 12082657
[TBL] [Abstract][Full Text] [Related]
9. Metabolic response to feeding in weight-losing pancreatic cancer patients and its modulation by a fish-oil-enriched nutritional supplement.
Barber MD; McMillan DC; Preston T; Ross JA; Fearon KC
Clin Sci (Lond); 2000 Apr; 98(4):389-99. PubMed ID: 10731472
[TBL] [Abstract][Full Text] [Related]
10. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
11. Daily physical-rest activities in relation to nutritional state, metabolism, and quality of life in cancer patients with progressive cachexia.
Fouladiun M; Körner U; Gunnebo L; Sixt-Ammilon P; Bosaeus I; Lundholm K
Clin Cancer Res; 2007 Nov; 13(21):6379-85. PubMed ID: 17975150
[TBL] [Abstract][Full Text] [Related]
12. Cyclooxygenase inhibition with acetylsalicylic acid unmasks a role for prostacyclin in erythropoietin-induced hypertension in uremic rats.
Rodrigue ME; Lacasse-M S; Larivière R; Lebel M
Can J Physiol Pharmacol; 2005 Jun; 83(6):467-75. PubMed ID: 16049546
[TBL] [Abstract][Full Text] [Related]
13. Leucine kinetics in patients with benign disease, non-weight-losing cancer, and cancer cachexia: studies at the whole-body and tissue level and the response to nutritional support.
Shaw JH; Humberstone DA; Douglas RG; Koea J
Surgery; 1991 Jan; 109(1):37-50. PubMed ID: 1984636
[TBL] [Abstract][Full Text] [Related]
14. Can erythropoietin improve tumor oxygenation?
Kelleher DK; Thews O; Vaupel P
Strahlenther Onkol; 1998 Dec; 174 Suppl 4():20-3. PubMed ID: 9879343
[TBL] [Abstract][Full Text] [Related]
15. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia.
Palazzuoli A; Silverberg D; Iovine F; Capobianco S; Giannotti G; Calabrò A; Campagna SM; Nuti R
Am Heart J; 2006 Dec; 152(6):1096.e9-15. PubMed ID: 17161060
[TBL] [Abstract][Full Text] [Related]
16. Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia.
Fearon KC; Barber MD; Moses AG; Ahmedzai SH; Taylor GS; Tisdale MJ; Murray GD
J Clin Oncol; 2006 Jul; 24(21):3401-7. PubMed ID: 16849754
[TBL] [Abstract][Full Text] [Related]
17. Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors.
Lundholm K; Gelin J; Hyltander A; Lönnroth C; Sandström R; Svaninger G; Körner U; Gülich M; Kärrefors I; Norli B
Cancer Res; 1994 Nov; 54(21):5602-6. PubMed ID: 7923204
[TBL] [Abstract][Full Text] [Related]
18. Epoetin omega for treatment of anemia in maintenance hemodialysis patients.
Sikole A; Spasovski G; Zafirov D; Polenakovic M
Clin Nephrol; 2002 Mar; 57(3):237-45. PubMed ID: 11924756
[TBL] [Abstract][Full Text] [Related]
19. NTP Toxicology and Carcinogenesis Studies of Salicylazosulfapyridine (CAS No. 599-79-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1997 May; 457():1-327. PubMed ID: 12587019
[TBL] [Abstract][Full Text] [Related]
20. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study.
Lundholm K; Gunnebo L; Körner U; Iresjö BM; Engström C; Hyltander A; Smedh U; Bosaeus I
Cancer; 2010 Apr; 116(8):2044-52. PubMed ID: 20186829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
